PRNewsWire
20 Nov 2025, 15:00 UTC · 44w ago
Verdict
Headline takes no side. We score SRPT −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Sarepta Therapeutics' late-stage ESSENCE trial for gene therapies AMONDYS 45 and VYONDYS 5 failed to meet statistical significance on its primary endpoint.
So whatFailure of late-stage clinical trials for primary products typically leads to significant loss of valuation and future revenue projections for biotech companies.
More negative than 99% of claims this week
Pomerantz LLP has launched an investigation into potential securities fraud or unlawful business practices by Sarepta and its officers.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company failed to meet statistical significance in a late-stage trial, leading to a 33.74% stock price drop and a securities fraud investigation.
More negative than 76% of ticker scores this week
The company is the subject of an investigation by Pomerantz Law Firm regarding potential claims on behalf of investors.
More negative than 76% of ticker scores this week
The company is the subject of an investigation by Pomerantz Law Firm regarding potential claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
+12.2%
Price is moving against the score
$18.39 vs $16.39 close before publication (Nov 19) · not market-adjusted
SRPT chart →
